CJC-1295 + Ipamorelin

History

CJC-1295 was developed as a long-acting analog of Growth Hormone-Releasing Hormone (GHRH) designed to extend the biological activity of endogenous GHRH signaling. Researchers sought to create a compound capable of producing sustained stimulation of growth hormone secretion through pituitary GHRH receptors. Ipamorelin was later developed as a highly selective growth hormone secretagogue that acts through activation of the ghrelin receptor (GHS-R1a). Its receptor specificity attracted significant scientific interest due to its targeted stimulation of growth hormone release. Researchers eventually began investigating the combination of CJC-1295 and Ipamorelin due to their complementary mechanisms of action. The peptide blend remains one of the most widely studied combinations in growth hormone and endocrine research.

Research Findings

CJC-1295 + Ipamorelin combines two investigational peptides that influence endogenous growth hormone secretion through distinct but complementary biological pathways. Researchers have extensively studied this combination to better understand growth hormone physiology and endocrine regulation. CJC-1295 functions as a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), stimulating growth hormone release through activation of pituitary GHRH receptors. Experimental studies have examined its effects on growth hormone secretion, insulin-like growth factor-1 (IGF-1) signaling, metabolic regulation, and endocrine physiology. Ipamorelin functions through activation of the growth hormone secretagogue receptor (GHS-R1a), commonly known as the ghrelin receptor. Researchers have investigated its ability to stimulate endogenous growth hormone release while maintaining a high degree of receptor selectivity. Scientific interest in the combination stems from the observation that GHRH receptor activation and GHS-R1a activation influence growth hormone secretion through separate physiological mechanisms. Experimental investigations have explored how simultaneous activation of both pathways affects growth hormone dynamics, endocrine signaling, and metabolic processes. Additional research has examined the relationship between growth hormone signaling and body composition, healthy aging, tissue maintenance, cellular adaptation, and metabolic regulation. These findings continue to drive interest in CJC-1295 + Ipamorelin as a research tool for studying growth hormone physiology. Further studies are necessary to fully characterize the biological interactions between these peptides and their broader applications within endocrine and metabolic research.

Key areas of research:

• Growth Hormone Research
• IGF-1 Research
• Endocrinology Research
• GHRH Research
• Ghrelin Receptor Research
• Metabolic Research
• Hormonal Signaling Research
• Healthy Aging Research
• Pituitary Function Research
• Growth Hormone Secretagogue Research

References

• CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone Analog
• Ipamorelin, the First Selective Growth Hormone Secretagogue

References are provided for research context only and do not constitute medical claims. CJC-1295 + Ipamorelin is sold for laboratory research use only.